Contenido principal del artículo

Marco Antonio Chalco Moscoso
Alicia Esperanza Zhingre Suárez

La hipertensión arterial (HTA) es una enfermedad crónica que afecta a más del 30% de la población adulta en todo el mundo y se caracteriza por tener una presión arterial más alta de lo normal. Se presentan los principales fármacos para el correcto manejo de la enfermedad según la gravedad de los síntomas del paciente evaluado por SCORE de riesgo cardiovascular y por sus patologías concomitantes. Objetivo. Identificar los fármacos y el tipo de tratamiento, farmacológico o no farmacológico, empleados en la HTA en cuanto a su diagnóstico, mejorando el manejo del paciente que padece esta enfermedad. Metodología. Se realizó una revisión de tipo sistemática empleando el protocolo PRISMA para la recopilación de información en trabajos procedentes de motores de búsqueda como PubMed, Scopus, Web of Science y ELSEVIER sobre el tratamiento de la Hipertensión Arterial Primaria, publicados durante enero del año 2017 hasta diciembre del año 2022. Conclusión. La hipertensión arterial sigue siendo un reto en el campo de la farmacología debido a su alta prevalencia y su asociación con múltiples enfermedades cardiovasculares. Los tratamientos disponibles son efectivos, pero no curan la enfermedad, por lo que es necesario seguir investigando nuevas opciones terapéuticas para mejorar el control y reducir el impacto en la salud pública. La educación y la prevención son herramientas importantes para reducir la incidencia de hipertensión y mejorar el manejo de la enfermedad. Con esta investigación fue posible identificar la importancia del tratamiento farmacológico y el tratamiento de tipo no farmacológico, evaluando adecuadamente el estado del paciente.

Arterial hypertension (AHT) is a chronic disease that affects more than 30% of the adult population worldwide and is characterized by higher than normal blood pressure. The main drugs for the correct management of the disease are presented according to the severity of the patient's symptoms evaluated by SCORE of cardiovascular risk and by his concomitant pathologies. Objective. To identify the drugs and the type of treatment, pharmacological or non-pharmacological, used in HT in terms of its diagnosis, improving the management of the patient suffering from this disease. Methodology. A systematic review was performed using the PRISMA protocol for the collection of information in works from search engines such as PubMed, Scopus, Web of Science and ELSEVIER on the treatment of Primary Arterial Hypertension, published during January 2017 until December 2022. Conclusion. Arterial hypertension remains a challenge in the field of pharmacology due to its high prevalence and association with multiple cardiovascular diseases. Available treatments are effective, but do not cure the disease, so it is necessary to continue investigating new therapeutic options to improve control and reduce the impact on public health. Education and prevention are important tools to reduce the incidence of hypertension and improve disease management. With this research it was possible to identify the importance of pharmacological treatment and non-pharmacological treatment, adequately assessing the patient's condition.

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Cómo citar
Chalco Moscoso, M. A., & Zhingre Suárez, A. E. (2023). Hipertensión arterial, un reto farmacológico. Revista Vive, 6(16), 251–263. https://doi.org/10.33996/revistavive.v6i16.223
Sección
ARTÍCULO DE REVISIÓN
Biografía del autor/a

Marco Antonio Chalco Moscoso, Universidad Católica de Cuenca. Cuenca, Ecuador

Médico interno, Universidad Católica de Cuenca, Ecuador.

Alicia Esperanza Zhingre Suárez, Universidad Católica de Cuenca. Cuenca, Ecuador

Magister en biotecnología molecular. Licenciada en laboratorio clínico, Universidad de Cuenca. Magister en biotecnología molecular, Universidad de Guayaquil, Ecuador.

Referencias

Jordan J, Kurschat C, Reuter H. Arterial Hypertension. Dtsch Arztebl Int. 2018;115(33-34):557-568. doi:10.3238/arztebl.2018.0557.

Vangen-Lønne AM, Wilsgaard T, Johnsen SH, Løchen ML, Njølstad I, Mathiesen EB. Declining Incidence of Ischemic Stroke: ¿What Is the Impact of Changing Risk Factors? The Tromsø Study 1995 to 2012. Stroke. 2017;48(3):544-550. doi:10.1161/STROKEAHA.116.014377.

Gao C, Cai Y, Zhang K, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41(22):2058-2066. doi:10.1093/eurheartj/ehaa433.

Al Ghorani H, Götzinger F, Böhm M, Mahfoud F. Arterial hypertension - Clinical trials update 2021. Nutr Metab Cardiovasc Dis. 2022;32(1):21-31. doi: 10.1016/j.numecd.2021.09.007.

Tousoulis D. Arterial hypertension: ¿New concepts in diagnosis and treatment? Hellenic J Cardiol. 2020;61(3):145-147. doi: 10.1016/j.hjc.2020.08.003.

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension [published correction appears in Eur Heart J. 2019 Feb 1;40(5):475]. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339.

Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends Cardiovasc Med. 2020;30(3):160-164. doi: 10.1016/j.tcm.2019.05.003.

Gyöngyösi H, K?rösi B, Batta D, et al. Comparison of Different Cardiovascular Risk Score and Pulse Wave Velocity-Based Methods for Vascular Age Calculation. Heart Lung Circ. 2021;30(11):1744-1751. doi: 10.1016/j.hlc.2021.06.518.

Manosroi W, Williams GH. Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms. Endocr Rev. 2019;40(3):825-856. doi:10.1210/er.2018-00071.

Topel ML, Duncan EM, Krishna I, Badell ML, Vaccarino V, Quyyumi AA. Estimated Impact of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines on Reproductive-Aged Women. Hypertension. 2018;72(4): e39-e42. doi:10.1161/HYPERTENSIONAHA.118.11660.

Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis [published correction appears in Lancet. 2021 May 22;397(10288):1884]. Lancet. 2021;397(10285):1625-1636. doi:10.1016/S0140-6736(21)00590-0.

Stergiou GS, Kario K, Kollias A, et al. Home blood pressure monitoring in the 21st century. J Clin Hypertens (Greenwich). 2018;20(7):1116-1121. doi:10.1111/jch.13284.

Roerecke M, Kaczorowski J, Myers MG. Comparing Automated Office Blood Pressure Readings With Other Methods of Blood Pressure Measurement for Identifying Patients With Possible Hypertension: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019;179(3):351-362. doi:10.1001/jamainternmed.2018.6551.

Camafort M, Alcocer L, Coca A, et al. Latin-American Ambulatory Blood Pressure Registry (MAPA-LATAM): An urgent need. Rev Clin Esp (Barc). 2021;221(9):547-552. doi: 10.1016/j.rceng.2021.02.004.

Sabbahi A, Severin R, Laddu D, Sharman JE, Arena R, Ozemek C. Nonpharmacological Management of Resistant Hypertension. Curr Cardiol Rep. 2021;23(11):166. Published 2021 Oct 1. doi:10.1007/s11886-021-01601-4.

Kucharska A, Gajewska D, Kiedrowski M, et al. The impact of individualised nutritional therapy according to DASH diet on blood pressure, body mass, and selected biochemical parameters in overweight/obese patients with primary arterial hypertension: a prospective randomised study. Kardiol Pol. 2018;76(1):158-165. doi:10.5603/KP. a2017.0184.

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757-1780. doi: 10.1016/j.jacc.2021.12.011.

Teo KK, Rafiq T. Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries. Can J Cardiol. 2021;37(5):733-743. doi: 10.1016/j.cjca.2021.02.009.

Verdecchia P, Reboldi G, Angeli F. The 2020 International Society of Hypertension global hypertension practice guidelines - key messages and clinical considerations. Eur J Intern Med. 2020; 82:1-6. doi: 10.1016/j.ejim.2020.09.001.

Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of Resistant and Refractory Hypertension. Circ Res. 2019;124(7):1061-1070. doi:10.1161/CIRCRESAHA.118.312156.

Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014;28(8):463-468. doi:10.1038/jhh.2013.140.

Seccia TM, Caroccia B, Maiolino G, Cesari M, Rossi GP. Arterial Hypertension, Aldosterone, and Atrial Fibrillation. Curr Hypertens Rep. 2019;21(12):94. Published 2019 Nov 18. doi:10.1007/s11906-019-1001-4.

Sinha AD, Agarwal R. Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. Clin J Am Soc Nephrol. 2019;14(5):757-764. doi:10.2215/CJN.04330418.

Gallo G, Volpe M, Rubattu S. Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations. Vasc Health Risk Manag. 2022; 18:507-515. Published 2022 Jul 11. doi:10.2147/VHRM.S337640.

Danaietash P, Verweij P, Wang JG, et al. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan. J Clin Hypertens (Greenwich). 2022;24(7):804-813. doi:10.1111/jch.14517.

Oparil S, Acelajado MC, Bakris GL, et al. Hypertension. Nat Rev Dis Primers. 2018; 4:18014. Published 2018 Mar 22. doi:10.1038/nrdp.2018.14.

Vargas-Uricoechea H, Cáceres-Acosta MF. Control of Blood Pressure and Cardiovascular Outcomes in Type 2 Diabetes. Open Med (Wars). 2018; 13:304-323. Published 2018 Aug 21. doi:10.1515/med-2018-0048.

Liang W, Ma H, Cao L, Yan W, Yang J. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med. 2017;21(11):2634-2642. doi:10.1111/jcmm.13205.

Fragakis A, Zhou J, Mannan H, Ho V. Association between Drug Usage and Constipation in the Elderly Population of Greater Western Sydney Australia. Int J Environ Res Public Health. 2018;15(2):226. Published 2018 Jan 29. doi:10.3390/ijerph15020226.

Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;(1):CD002003. Published 2007 Jan 24. doi: 10.1002/14651858.CD002003.pub2.

Shuey M, Perkins B, Nian H, Yu C, Luther JM, Brown N. Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data. BMJ Open. 2020;10(5): e033100. Published 2020 May 26. doi:10.1136/bmjopen-2019-033100.

Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A. Spironolactone. J Pain Symptom Manage. 2017;53(2):288-292. doi: 10.1016/j.jpainsymman.2016.12.320.

Kim C. Management of Cardiovascular Risk in Perimenopausal Women with Diabetes. Diabetes Metab J. 2021;45(4):492-501. doi:10.4093/dmj.2020.0262.